Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1097

Shown on this page

Current sort

Live official records

Conditions: AML, ALL, MDS
Interventions: Observational; Other
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 2
States / cities: Duarte, California • New York, New York

Conditions: Tracheostomy
Interventions: 3 Oz water screen; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Mandibular Reconstruction, Segmental Mandibular Defects
Interventions: Surgical Resection and Reconstruction; Procedure
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2022 – 2030
U.S. locations: 5
States / cities: Jacksonville, Florida • Chicago, Illinois • New Hyde Park, New York + 2 more

Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Interventions: Pembrolizumab, FF-10832; Drug
Lead sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 23
States / cities: Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Prostate Cancer
Interventions: Dehydrated alcohol, Lidocaine IV; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycythemia Vera
Interventions: P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101); Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Jacksonville, Florida • Fort Wayne, Indiana • Westwood, Kansas + 14 more

Conditions: Urothelial Carcinoma
Interventions: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Gemcitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Advanced Solid Tumor
Interventions: SGR-3515; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 9 more

Conditions: Cocaine Use Disorder
Interventions: Cognitive Reappraisal, Control cue-reactivity task; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Methamphetamine Use Disorder
Interventions: Cognitive Reappraisal; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions: Percutaneous Coronary Intervention (PCI); Procedure
Lead sponsor: University of British Columbia; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 55
States / cities: Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more

Conditions: Myelofibrosis (MF)
Interventions: ABBV-744, Navitoclax, Ruxolitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Live official records

A Long Term Follow-up Study of TScan TCR-T Products

Investigation of a 3 oz Water Protocol on Patients With Tracheostomies

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Long Acting Neuraxial Peri-prostatic Block in Cancer

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Study of SGR-3515 In Participants With Advanced Solid Tumors.

Cocaine Cue-reactivity Incubation Study

Methamphetamine Cue-reactivity

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

About this Mount Sinai institution page